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PCARDIOVASCULAR GENOMIC MEDICINE
Genetic Testing in Cardiovascular Disease
Nathaniel H. Robin, MD,* Paul B. Tabereaux, MD, MPH,† Raymond Benza, MD,†
Bruce R. Korf, MD, PHD*
Birmingham, Alabama
Genetic testing is increasingly becoming possible for diagnosis, susceptibility testing, and prognostication in car-
diovascular medicine. The practicing cardiologist, therefore, needs to be familiar with the clinical utilities and
limitations of genetic testing. This review explores the major approaches to genetic testing and issues in test
interpretation. Specific applications to cardiovascular diseases, including coronary artery disease, cardiomyopa-
thies, cardiac arrhythmias, and pulmonary arterial hypertension are discussed. (J Am Coll Cardiol 2007;50:
727–37) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.015a
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idvances in molecular genetics, and especially the sequenc-
ng of the human genome, are rapidly adding genetic tests to
he armamentarium of diagnostic and predictive tools avail-
ble for the management of cardiovascular disease. Genetic
ests offer many advantages over traditional tests. They do
ot require invasive sampling, have high accuracy, and can
e done at any time in life, whether or not symptoms of
isease are present. Most physicians were trained before the
dvent of genetic testing and are unfamiliar with indications
nd intricacies of interpretation. Although the physician
oes not need to be intimately familiar with the details of
enetic testing to appropriately order and interpret tests,
ome appreciation of the indications and limitations of
enetic tests can help to insure that they are used to
aximum benefit. In this review we will first provide
ackground on the major approaches to genetic testing and
he pitfalls in interpretation. We will then consider the role
f genetic testing for the evaluation of patients with coro-
ary artery disease (CAD), cardiomyopathies (CMs), car-
iac arrhythmias, and pulmonary arterial hypertension
PAH). For each we will highlight the benefits and the
imitations of testing and discuss what the future may bring.
eneral Principles of Genetic Testing
or purposes of this review, genetic testing is defined as the
nalysis of chromosomes, deoxyribonucleic acid, or ribonu-
leic acid to identify genetic variants that may be of medical
ignificance. Most genetic tests involve direct detection of a
utation responsible for disease or risk of disease. Linkage-
ased tests rely on use of genetic markers that reside nearby
rom the *Department of Genetics and †Division of Cardiology, Department of
edicine, University of Alabama at Birmingham, Birmingham, Alabama. Cardio-
ascular Genomic Medicine series edited by Geoffrey S. Ginsburg, MD, PhD.a
Manuscript received May 19, 2006; revised manuscript received April 16, 2007,
ccepted May 1, 2007.gene of interest to track inheritance of the gene in a family.
his approach is used less often as the genes involved in
isease risk are increasingly amenable to direct testing. A
hird approach, referred to as genomic testing, involves
nalysis of multiple genetic variants or products of gene
xpression to obtain an overall “genomic fingerprint” of an
ndividual or tissue sample. This approach is in its infancy
nd will not be discussed further in this review.
Indications for genetic testing include 4 distinct applica-
ions: diagnostic testing, presymptomatic testing, predispo-
itional (susceptibility) testing, and pharmacogenetic test-
ng. Diagnostic testing is performed on an individual having
igns and/or symptoms of disease with the goal of estab-
ishing a precise diagnosis. A genetic test can establish a
iagnosis without the need to sample affected tissue and can
erve as the basis for treatment, anticipatory guidance, and
enetic counseling. Presymptomatic testing is applied to
ndividuals who do not yet have signs or symptoms of
isease, but are known to be at risk on the basis of family
istory. Genetic testing can determine risk of disease, but
oes not guarantee that disease will become symptomatic.
redispositional (susceptibility) testing applies to multifac-
orial disorders, where multiple genes interacting with one
nother and with the environment contribute to disease.
ajor research efforts are now being directed toward iden-
ification of genetic variants that can be used to predict risk
f disease. Pharmacogenetic testing involves analysis of
enes responsible for the metabolism and activity of drugs.
harmacogenetic tests are likely to be used in the future to
atch the choice of drug to specific physiological targets,
roviding a greater likelihood of efficacy and fewer side
ffects.
The ability to offer a genetic test is not sufficient reason to
nclude it in routine medical practice. Evaluation of a test
ncludes consideration of analytical validity, clinical validity,
nd clinical utility. Analytical validity is defined as the
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sults are correct (e.g., a specific
genetic variant is present or ab-
sent). Genetic tests tend to have
a high degree of analytical valid-
ity, barring human errors such as
sample mix-up. Clinical validity
is the degree to which the test
correctly assesses the risk of
health or disease. Genetic tests
may reveal variants of unknown
significance, and often do not
identify all possible mutations;
therefore, false-positive or false-
negative results may occur. Clini-
cal utility is the degree to which
the test guides medical manage-
ment. There are many instances
where a test can be performed to
indicate risk of disease, yet there
is no approach to management
that improves outcome based on
the results of testing. Genetic
testing must also be viewed in
the context of ethical, legal, and
social concerns, including risks of
stigmatization, discrimination,
anxiety, guilt, and so on.
CAD and
Myocardial Infarction (MI)
Coronary artery disease is the
leading cause of death in the
world, affecting 13,000,000 peo-
ple in the U.S. alone (1,2). As
such, it is a major public health
concern, and significant efforts
have sought to reduce the mor-
tality and morbidity associated
with CAD. These efforts have
focused primarily on modifica-
ion of environmental and behavioral risk factors, including
edentary lifestyle, smoking, obesity, and high-fat diet.
odifying these behaviors is extremely important, and has
een shown to reduce cardiovascular mortality and morbid-
ty. Nonetheless, family history remains the single strongest
ndependent risk factor for development of CAD (3).
owever, in most cases this risk cannot be determined more
recisely. The information gained through a detailed family
istory does not identify specific interventions to limit risk,
or can it assist in determining a treatment plan. Thus,
dentification of specific genetic risk factors is essential for
ore precise risk determination, as well as individualization
f therapy. Testing for such factors will be beneficial not
Abbreviations
and Acronyms
ARVC  arrythmogenic
right ventricular
dysplasia/cardiomyopathy
CAD  coronary artery
disease
CM  cardiomyopathy
CPVT  catecholaminergic
polymorphic ventricular
tachycardia
DCM  dilated
cardiomyopathy
DCM-CCD  dilated
cardiomyopathy associated
with cardiac conduction
defects
FDCM  familial dilated
cardiomyopathy
FH  familial
hypercholesterolemia
HCM  hypertrophic
cardiomyopathy
INVM  isolated
noncompaction of the
ventricular myocardium
LDL  low-density
lipoprotein
LDLR  low-density
lipoprotein receptor
LQTS  long QT syndrome
MI  myocardial infarction
PAH  pulmonary arterial
hypertension
PCCD  progressive
cardiac conduction defect
PPH  primary pulmonary
hypertension
RCM  restrictive
cardiomyopathy
SNP  single nucleotide
polymorphismnly for those with a positive family history, but also could senefit healthy individuals with no family history. Although
uch uses of genetic tests are not currently available, the pace
f discovery promises clinically useful tests in the near
uture.
he difficulty of finding CAD-related genes. The last
ew years have seen a remarkable series of advances in our
nderstanding of the role of genetics in cardiac diseases.
isease-causing gene mutations have been identified in
pproximately two-thirds of cases of hypertrophic cardio-
yopathy (HCM), nearly that much of dilated cardiomy-
pathy (DCM), and most instances of familial cardiac
rrhythmias (4). Understanding the genetic basis of CAD,
owever, has proven more elusive. Except for rare forms
hat follow a Mendelian inheritance pattern, CAD is a
ultifactorial trait, caused by both genetic and environmen-
al factors. Unlike single gene disorders, genetic studies of
omplex traits such as CAD are compounded by the lack of
perfect cosegregation between the risk allele and the
henotype and the high prevalence of the risk allele in the
opulation. In a complex trait, the presence of a risk allele is
either necessary nor sufficient to cause the phenotype, and,
ence, establishing causality is difficult. This is particularly
he case for the results of allelic association studies per-
ormed with selective single nucleotide polymorphisms
SNPs) in small populations. The results of such studies are
ot sufficiently conclusive to confer clinical utility. The
ifficulty, while common to complex traits, also extends to
AD with a Mendelian inheritance pattern, as was recently
emonstrated for the putative role of MEF2A in suscepti-
ility to CAD.
MEF2A was identified through study of a large family
ith multiple members with early-onset CAD (5). It was
ssumed in this family that CAD was inherited as an
utosomal dominant trait, and linkage analysis mapped the
ausative gene to a segment on chromosome 15q26, a region
hat contained 93 genes. In 1 of those genes, MEF2A, a
1-base pair deletion was identified in the members of this
amily that cosegregated with inheritance of CAD. MEF2A
as also considered to be an attractive candidate gene
ecause it is expressed in the developing vasculature of
mbryonic mice. In a follow-up study, 3 different genetic
ariations were identified among 207 individuals with
AD. The investigators suggested that MEF2A was a
ignificant contributor to CAD, accounting for almost 3%
f cases (5). A subsequent study called these findings into
uestion (6), however. Not only did the investigators fail to
dentify variations in MEF2A among 300 patients with
remature CAD, but they also found the same 21-base pair
eletion in an elderly control subject. These findings cast
oubt on the original association of MEF2A as an important
ene in CAD, but more importantly highlight the difficulty
n gene identification for complex traits like CAD (7).
Although the association of MEF2A and CAD remains
nresolved, a number of other genes have been implicated in
usceptibility to CAD (4). These can be divided into 2
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August 21, 2007:727–37 Genetic Testing in CVDroups: genes in which mutations directly cause CAD and
hose that convey a risk for (or protection from) CAD.
mong the best-established genetic risk factors for CAD
re single-gene disorders affecting plasma levels of low-
ensity lipoprotein (LDL) cholesterol and high-density
ipoprotein cholesterol. Genes responsible for familial hy-
ercholesterolemia (FH) and Tangier disease are the pro-
otypic examples of causal genes for CAD and MI. Familial
ypercholesterolemia is an autosomal dominant disorder
hat is characterized by severe elevations in total serum
holesterol and LDL cholesterol. Cholesterol deposition
ccounts for the associated findings, which include tendon
anthomas and atheromas, and markedly elevates the risk
or CAD and MI. The underlying defect is in the LDL
eceptor, which is responsible for the majority of uptake of
irculating LDL by the liver. Familial hypercholesterolemia is
n uncommon disorder, affecting 1 in 500 persons worldwide.
omozygosity for an associated FH mutation produces mark-
dly elevated LDL and cholesterol levels, leading to progressive
AD and MI in the first decade of life. Familial hypercholes-
erolemia is genetically heterogeneous, and can be caused by
utations in a number of genes. These include the genes for
he low-density lipoprotein receptor (LDLR), ApoB-100,
CSK9, CYP7A1, and ARH.
Tangier disease is a rare autosomal recessive disorder that
nvolves diffuse deposition of cholesterol esters throughout the
eticuloendothelial system. The disorder is associated with the
lassic manifestation of enlarged yellow tonsils. It is character-
zed by low-to-absent plasma high-density lipoproteins and
ow cholesterol, due to mutations in ABCA1 gene.
The genes for these diseases were identified by linkage
nalysis, as each segregates in a Mendelian pattern with a
lear marker for the presence of the mutant gene. For each
isorder, clinical genetic testing is available. Efficacy of
esting is limited to confirmation of the clinical diagnosis in
patient with an abnormal lipid profile, or for prenatal
iagnosis. The real power of genetic testing is to identify
t-risk individuals who cannot be otherwise identified, since
hey lack other clinical or laboratory markers.
usceptibility genes for CAD. While mapping the causal
ene for a monogenic disease is relatively simple, the process
f mapping the susceptibility genes for a complex trait such
s CAD is quite complex. The process is compounded by
he lack of perfect cosegregation of a genetic marker with
nheritance of CAD, genetic heterogeneity of CAD, low
enetrance of the susceptibility allele, and high frequency of
usceptibility alleles in the population. Accordingly, enthu-
iasm for the results of any single allelic association study for
AD must be tempered until it has been replicated and
alidated. In general, SNPs in genes regulating plasma levels of
ipoproteins, inflammatory markers, and coagulation factors
re the prime susceptibility alleles for CAD and MI. For
xample, apoE4 is among the most commonly established risk
actors for CAD. Another example is the upstream transcrip-
ion factor 1 gene (USF1), which has been linked to familialombined hyperlipidemia (8). Familial combined hyperlipid-
mia is characterized by elevated total serum cholesterol and
riglycerides and is found in 20% of patients with CAD.
everal genes involved in the inflammatory response may also
e related to the development of CAD. Examples include
NPs in the genes encoding cytokine gene lymphotoxin-
LTA), 5-lipoxygensae–activating protein (ALOX5AP), and
hosphodieterase 4D (PED4D) (9–11). However, the results
ave not been concordant in all studies (12). Recently, an SNP
as identified that seems to confer a protective effect from
AD. The gene, LGALS2, is a regulator of other inflamma-
ory genes, including LTA. This common polymorphism
auses a 50% decrease in gene expression, and was found to be
ssociated with a reduced risk for CAD (13). Although
ntriguing, this finding has yet to be confirmed.
linical applications. Genetic testing is expected to afford
he opportunity for assessment of individual’s risk profile,
ot only in members of high-risk families but also in the
eneral population, as part of routine health care. The
xpectation is that it will be possible to lower the risk for
AD, either by specific drug therapy, lifestyle modification,
r a combination of both.
For individuals already affected by CAD, identifying the
enetic basis might permit a particular therapy that targets
he specific pathogenic mechanism underlying atherogene-
is. Along these lines, research for 2 genes, ALOX5AP
ncoding arachidonate 5-lipooxygenase–activating protein,
r FLAP, and leukotriene A4 hydrolase, now show promise
or more specific therapies (14,15). A randomized placebo-
ontrolled crossover study was conducted on the effects of a
eukotriene inhibitor DG-031 in 191 patients with prior MI
ho had the at-risk genotypes for ALOX5AP and leukotri-
ne A4 hydrolase. Patients in the treatment group showed
eduction in circulating inflammatory biomarkers, suggest-
ng a beneficial effect for this genetic subtype of CAD
atients. This is among the first of what will be many trials
hat seek to translate genetic discovery to clinical utility (16).
ecommendations:
. At present, there are no commercially available genetic tests for
variants associated with CAD orMI that are recommended for
routine care. Several academic medical centers are currently
offering clinical trials for families or individuals at elevated risk
for CAD or MI to help further elucidate useful gene or protein
targets for risk stratification or pharmacogenetic approaches to
care.
. Testing is available for FH specifically targeting the LDLR
gene by DNA-sequencing and Apo-B by mutation analysis.
Genotypic-positive individuals should still be managed
based on routine cholesterol assays and cholesterol guidelines;
however, the likelihood for required multiple drug therapy is
elevated. Patients and families affected by FH may benefit
from genetic testing by providing early screening for the
phenotypic appearance of elevated cholesterol levels and
risk-factor modification before onset of disease (17).
CT
h
T
C
M
f
g
a
a
d
p
D
c
a
t
c
r
dilate
730 Robin et al. JACC Vol. 50, No. 8, 2007
Genetic Testing in CVD August 21, 2007:727–37Ms
he pace of genetic discovery for the various forms of CMs
as proceeded rapidly, far greater than for CAD (Table 1).
his is because, unlike the complex genetic inheritance for
AD, the genetically determined CMs tend to follow
endelian inheritance patterns. Therefore, the strategies
or identifying CM genes are more straightforward. In turn,
enetic testing for variants associated with CM is far more
dvanced, with tests for several forms of CM already
Genes Associated With Cardiomyopathy
Table 1 Genes Associated With Cardiomyop
Disorder
DCM
Pure familial DCM
DCM with ventricular tachycardia
DCM with wooly hair and keratoderma
DCM plus cardiac conduction defects (Emery-
Dreifuss muscular dystrophy)
X-linked DCM (Duchene/Becker muscular dystrophy)
X-linked DCM (also Barth syndrome, isolated
noncompaction of the ventricular myocardium)
Isolated noncompaction of the ventricular myocardium
HCM (192600)
HCM
HCM and DCM
Primarily causes HCM; only 1 patient with DCM
Arrythmogenic right ventricular dysplasia
*Clinical testing is available.
AD  autosomal dominant; AR  autosomal recessive; DCM 
mitochondrial; XLR  X-linked recessive.vailable clinically. DCardiomyopathy is typically divided into several subtypes:
ilated, hypertrophic, arrythmogenic right ventricular dys-
lasia, restrictive, and unclassified (18).
CM. Dilated cardiomyopathy is characterized by an in-
rease in left ventricular end-diastolic diameter (2.7 cm/m2)
nd reduced left ventricular systolic function (ejection frac-
ion of 0.45). Dilated cardiomyopathy is among the most
ommon causes of heart failure in the young and a major
eason for cardiac transplantation. The overall prevalence of
Inheritance
Pattern Gene Product
AD actin
AD desmin
AD -sarcoglycan
AD tropinin T
AD -myosin heavy chain*
AD CSRP3
AD phospholamban
(1 case) TCAP
(2 cases) ABCC9
AR desmoplakin
AD lamin A/C*
XLR dystrophin*
XLR tafazzin*
AD -dystrobrevin
AD Cypher/ZASP
AD lamin A/C*
AD -tropomyosin*
AD cardiac myosin-binding protein C*
AD -myosin heavy chain*
AD tropinin T
AD myosin light chain
AD cardiac troponin I
AD myosin light chain 3
AD titan
AD myosin heavy chain-
Mito tRNA-glycine
Mito tRNA-isoleucine
AD cardiac myosin-binding protein
AD -myosin heavy chain*
AD actin
AD cardiac myosin light-peptide kinase
AD caveolin-3
AD -tropomyosin
AD ryanodine receptor
AD desmoplakin
AD plakophilin 2
d cardiomyopathy; HCM  hypertrophic cardiomyopathy; Mito athyCM in the U.S. is 36.5/100,000 (2). About 35% to 50%
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August 21, 2007:727–37 Genetic Testing in CVDf cases have a positive family history (19). In addition,
bout 10% of asymptomatic relatives of probands with
CM have evidence of unrecognized left ventricular dys-
unction (20). Every inheritance pattern has been noted,
ncluding autosomal dominant and recessive, X-linked, and
aternal (mitochondrial) forms, although the autosomal
ominant forms are the most common.
Familial dilated cardiomyopathy (FDCM) can be further
ivided into 2 subtypes—isolated FDCM and FDCM with
ardiac conduction defects. Both exhibit genetic heteroge-
eity, as over a dozen different chromosomal loci have
een mapped to contain DCM-related genes (Table 1).
utations in several genes have been associated with
solated (pure) DCM, including the genes encoding cardiac
ctin, desmin, -sarcoglycan, -sarcoglycan, cardiac tropo-
in T, -tropomyosin, -myosin heavy chain, and cardiac
yosin-binding protein C gene (21) (Table 1). Mutations
n many of the genes that cause DCM also can cause HCM,
s illustrated by mutations in -myosin heavy chain and
ardiac troponin T (22).
Dilated cardiomyopathy associated with cardiac conduc-
ion defects (DCM-CCD) is an autosomal dominant con-
ition that typically presents in the second decade with mild
ardiac conduction defects, which often progress to com-
lete heart block. Unrecognized progression to complete
eart block can cause sudden cardiac death. Atrial conduc-
ion defects and atrial fibrillation occur in a significant
umber of patients. Dilated cardiomyopathy develops inde-
endently of the conduction defect. Four loci have been
apped that contain DCM-CCD genes, but only 1, lamin
/C, has been identified (23). Mutations in lamin A/C also
ause a variety of disorders, including Emery-Dreifuss
uscular dystrophy and a mild skeletal myopathy associated
ith FDCM. Clinical testing for mutations in lamin A/C is
vailable.
There are several forms of X-linked DCM. Duchene and
ecker muscular dystrophies are the prototypic representa-
ives of X-linked DCM. The phenotype is due to progres-
ive degeneration of muscle function and often starts as mild
ut progressive skeletal myopathy and DCM. Duchene and
ecker muscular dystrophies present in early childhood
Duchenne) or later in life (Becker), and for each, DCM is
later-onset manifestation (24). Cardiac involvement in-
ludes atrioventricular block, which is progressive; atrial
rrhythmia and standstill; wall motion abnormalities; and
CM. Dilated cardiomyopathy may be the only cardiac
anifestation of Duchenne/Becker muscular dystrophy.
ilated cardiomyopathy is present in approximately 90% of
he advanced cases. Dilated cardiomyopathy presents with
apidly progressive disease in men in the second decade,
nding in death or cardiac transplantation (25,26). Female
arriers usually present in their 50s with a milder and more
lowly progressive disease (26). The causal gene is dystro-
hin, which codes for a large cytoskeletal protein. The
pectrum of mutations includes point, deletion, and inser-
ion mutations or gene rearrangements. Frameshift muta- cions are associated with a severe form, while missense
utations or in-frame deletions or duplications often lead to
mild form of the disease.
The second form of X-linked DCM is seen as part of Barth
yndrome. This disorder is characterized by neonatal heart
ailure, neutropenia, and myopathy (27). Urine organic acid
nalysis demonstrates elevations in 3-methylglutaconic acid,
nd mitochondrial abnormalities are seen by electron micros-
opy and functional studies (28). The type of cardiac defect
s variable, including endocardial fibroelastosis, DCM, and
oncompaction of the ventricular myocardium. Susceptibil-
ty to infection may prove fatal in the neonatal period, but
ost children survive and the DCM typically persists (27).
he gene for Barth syndrome is G4.5, encoding tafazzin, a
rotein of unknown function (29). Different mutations in
his gene can cause X-linked infantile DCM and endocar-
ial fibroelastosis, as well as isolated noncompaction of the
entricular myocardium (INVM) (30,31).
Dilated cardiomyopathy is also part of the phenotypic
xpression of Emery-Dreifuss muscular dystrophy, which is
n X-linked disorder characterized by progressive skeletal
nd cardiac myopathy. Cardiac involvement also includes
rrhythmia, conduction defects, and sudden cardiac death.
he responsible gene is EMD, which encodes emerin.
merin is a member of the nuclear lamina-associated
rotein family.
ecommendations:
. Genetic testing and mutation screening is not yet available
for routine use, partly because of the extensive genetic
heterogeneity of the disease. However, genetic diagnosis and
mutation screening could be performed in families with
several affected members through linkage analysis and
screening of the candidate genes in the mapped locus.
. The prevalence of causal genes and mutations has yet to
be determined. Therefore, given the allelic and locus
heterogeneity, routine genetic testing is not feasible in
sporadic cases.
. An electrocardiogram (ECG) and echocardiogram should be
performed on family members of those with idiopathic
DCM for screening. Up to 25% of family members may
show abnormalities, including isolated left ventricular en-
largement with or without systolic dysfunction. Patients
with left ventricular enlargement and normal systolic
function should be monitored routinely with echocardiography
(32).
CM. Hypertrophic cardiomyopathy is a primary disorder
f cardiac myocytes, clinically recognized by the presence of
ardiac hypertrophy in the absence of an increased external
oad. Pathologically, it is characterized primarily by the triad
f myocyte hypertrophy, disarray, and interstitial fibrosis.
ardiac hypertrophy is asymmetric in approximately two-
hirds of the cases, with the septum being the predominant
ite of involvement. Global systolic function is increased and
iastolic function is impaired. In approximately 25% of the
ases, there is significant left ventricular outflow tract
o
t
g
H
t
i
m
g
c
b
a

a
c
g
p
d
T
t
d
h
h
d
g
c
w
h
H
a
p
a
e
c
f
i
m
H
c
h
c
a
w
a
d
c
h
t
F
t
o
(
o
c
i
i
s
F
t
b
s
g
d
R
1
2
3
A
(
c
m
t
i
r
h
r
m
i
i
n
o
y
5
i
t
732 Robin et al. JACC Vol. 50, No. 8, 2007
Genetic Testing in CVD August 21, 2007:727–37bstruction (19). Hypertrophic cardiomyopathy is a rela-
ively common disorder: 1 study (33) found echocardio-
raphic evidence of HCM in 1 of 500 young adult subjects.
ypertrophic cardiomyopathy most commonly presents in
he 10- to 25-year age group, but presentation in infancy or
n later adulthood is also seen.
Hypertrophic cardiomyopathy is a disease of the sarco-
ere, the basic unit of the heart muscle (34). The causal
enes all encode sarcomere proteins: -myosin heavy chain,
ardiac regulatory and essential myosin light chains, myosin
inding protein C, -cardiac actin, -tropomyosin, titan,
nd cardiac troponins T, I, and C (19). Mutations in the
-myosin heavy chain and myosin-binding protein C genes
ccount for approximately 60% of familial and sporadic
ases (35). Clinical testing for variants in most of these
enes is available, and can provide valuable therapeutic and
rognostic information (36).
Limited genotype-phenotype correlations were initially
escribed from large multigenerational family studies.
hese findings included troponin T mutations, which are
ypically associated with a high risk of sudden cardiac
eath, despite the apparent mild or even subclinical
ypertrophy. Mutations in myosin-binding protein C
ave been associated with a milder and later onset
isease. Some mutations in the -myosin heavy chain
ene are associated with mild or even benign clinical
ourse, while others cause a malignant form of HCM
ith presentation in early childhood, rapid progression of
ypertrophy, and increased risk for sudden death (35).
owever, these findings have been observed consistently,
nd various clinical manifestations have been reported in
atients with identical causal genes and mutations. Over-
ll, there is considerable variability in the phenotypic
xpression of HCM, which is partly determined by the
ausal genes and mutations and partly by various modi-
ying factors (37). The identity of these modifying factors
s not fully known, but may include lifestyle, environ-
ent, genes, or epigenetic factors.
CM phenocopy. Several other genetic disorders include
ardiac hypertrophy as one component. Although cardiac
ypertrophy in these conditions appears similar to HCM
aused by sarcomeric mutations on echocardiographic ex-
mination, differences are apparent on tissue histology as
ell as pathogenesis. Therefore, the phenotype is referred to
s HCM phenocopy and not true HCM. Examples of such
isorders include glycogen storage diseases, respiratory
hain enzyme defects, and Fabry disease. While cardiac
ypertrophy is a serious complication for these disorders,
he conditions typically present with other abnormalities.
abry disease is worth noting, as studies have shown that up
o 6% of affected men have HCM phenocopy (38), and 12%
f carrier women may develop later-onset HCM phenocopy
39). Fabry CM may also present as a restrictive cardiomy-
pathy (RCM). Fabry disease is an X-linked disorder
aused by accumulation of glycosphingolipid due to a defect
n the enzyme -galactosidase A. Predominant symptoms rnvolve the skin, kidneys, and central nervous system; one
ubtype presents primarily with cardiac manifestations.
abry disease is one of the few genetic disorders for which
here is a specific treatment. Enzyme replacement therapy
y regular infusions of agalsidase beta (Fabrazyme) has been
hown to reduce symptoms and even reverse disease pro-
ression (40). Such therapy must be maintained for life, or
isease progression will resume.
ecommendations:
. Mutation analysis for the 8 sarcomeric genes is now
commercially available for clinical testing (however, the cost
may be prohibitive [total cost $4,000]), as many insur-
ance companies do not cover the test. Furthermore, due to
the heterogeneity of the HCM, a negative test does not
exclude the possibility that an individual’s HCM is due to
a mutation in a gene that was not tested.
. Maron et al. (33) have proposed a screening mechanism for
high-risk individuals (e.g., those with family history of
HCM) who are unable to utilize genetic testing, either
because of cost/insurance issues or because the mutation could
not be identified in an affected family member. In such
families, adolescents between the ages of 12 to 21 years
should have ECG and echocardiography screening on a 12-
to 18-monthly basis. Patients under the age of 12 years
require screening only if high-risk features such as malig-
nant family history of premature HCM death/complication,
they are a competitive athlete, or symptoms or clinical
suspicion of early left ventricular hypertrophy exist. Patients
older than 21 should continue ECG and echocardiography
examinations every 5 years to exclude a late-onset HCM
presentation.
. Based on a readily available therapy and simplicity of the
testing, patients with unexplained concentric left ventricu-
lar hypertrophy should be screened for Fabry disease with a
plasma alpha-galactosidase A level.
rrythmogenic right ventricular dysplasia/cardiomyopathy
ARVC). Arrythmogenic right ventricular dysplasia/
ardiomyopathy is characterized by fibrofatty replacement of
yocytes predominantly in the right ventricle, and some-
imes in the left ventricle. This replacement may be local-
zed, and can result in the formation of ventricular aneu-
ysms in affected areas (41). Cardiac failure, initially right
eart failure and in advanced cases left heart failure, may
esult. In the latter situation, the clinical presentation may
imic DCM. Sudden cardiac death due to an arrhythmia
s a more common cause of death, especially in younger
ndividuals. Although the exact prevalence of this disorder is
ot known, ARVC may be the second most common cause
f sudden unexpected cardiac death in otherwise healthy
oung adults (34).
A history of affected family members is found in 30% to
0% of patients (42) and follows an autosomal dominant
nheritance pattern. An autosomal recessive form in conjuc-
ion with skin and hair disorders also has been described and
eferred to as cardiocutaneous syndrome. To date, 8 chro-
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August 21, 2007:727–37 Genetic Testing in CVDosomal loci have been mapped (43), and 4 genes encoding
esmosomal proteins have been identified: plakoglobin (44),
esmoplakin (45), desmoglein 2, and plakophilin 2 (46).
ecently, mutations in plakophilin 2 were shown to be the
ost common cause, found in over one-half of cases in one
tudy (42). Mutations in ryanodine receptor 2 cause cat-
cholaminergic polymorphic ventricular tachycardia (CPVT),
hich could mimic ARVC (phenocopy) (47). Mutations in
he regulatory regions of transforming growth factor 3 have
een associated with ARVC (48), but causality has not been
stablished.
ecommendations:
. Current data raise the possibility of routine genetic testing
for variants associated with ARVC. Screening of the 4
known genes encoding desmosomal proteins could lead to
identification of the causal mutation in about two-thirds of
the cases. However, there is no commercially available
genetic test for diagnosis of ARVC.
CM. Restrictive cardiomyopathy is a primary myocardial
isease, characterized by impaired ventricular diastolic fill-
ng, normal or small ventricles, enlarged atria, and often
reserved global systolic function. The clinical phenotype of
CM also occurs in various conditions such as amyloidosis,
arcoidosis, and Fabry disease.
Familial RCM exhibits an autosomal dominant form of
nheritance. It could occur in conjunction with skeletal
yopathy and atrioventricular conduction defects. Two
ausal genes, namely DES and TNNI3, which encode
esmin and cardiac troponin I, have been identified.
esmin is an intermediary filament that is also involved in
esminopathies, involving skeletal muscles as well as the
eart. Mutations in TNNI3, which are known to cause
CM and DCM, also cause RCM. Restrictive cardiomy-
pathy also occurs in patients with Noonan syndrome, a
isease caused by mutations in protein tyrosine phosphatase,
onreceptor type II. The utility of genetic testing in RCM
emains to be established.
nclassified CMs. Isolated noncompaction of the ventric-
lar myocardium is a poorly understood, rare, but probably
nderdiagnosed disorder. It is often diagnosed phenotypi-
ally as DCM or HCM. The characteristic manifestations
nclude prominent trabeculation and deep recesses within
he endocardium in the absence of coexisting structural
eart anomalies (49,50). Isolated noncompaction of the ven-
ricular myocardium is diagnosed based on echocardiographic
ndings of segmental thickening of the left ventricular
yocardial wall with a ratio of noncompacted to compacted
yocardium of 2:1 at end-systole. It is genetically distinct
rom the NVM associated with Barth syndrome (51).
solated noncompaction of the ventricular myocardium is
hought to be a developmental anomaly, an arrest of in utero
ardiac muscle development.
The clinical presentation for INVM is variable. Early
eports suggest a poor prognosis, with a high rate of
rogression to heart failure and death or transplantation. cowever, subsequent reports have shown that INVM is, in
act, associated with a variable clinical course (50,52,53).
Isolated noncompaction of the ventricular myocardium is
enetically heterogeneous. To date, 4 different genes and 1
enetic locus have been associated with INVM. In addition
o G4.5, these include alpha-dystrobrevin (DNTA) (54),
ypher/ZASP (55), and lamin A/C (LMNA) (56). Only a
mall percentage of cases to date have been found to have
utations in any of these 4 genes, with most being
ssociated with G4.5/TAZ (31,51). Recent linkage analysis
f a family with INVM has identified an additional locus on
1p15 that is associated with autosomal dominant INVM in
family (57). The range of clinical variability is, as yet, not
nown (58).
ecommendations:
. While several genes are known, there is insufficient data to
advocate genetic testing for diagnosis and prognostication in
INVM.
. Family screening by genetic studies is at present not
recommended. Echocardiographic screening of family mem-
bers of affected individuals is recommended (59).
amilial cardiac arrhythmias. Like CM, many genes in-
olved in familial arrhythmias have been identified in the
ast 15 years. Genetic studies have illustrated the genetic
eterogeneity of the phenotypes, clinically recognized as a
ingle entity. In addition, genetic studies suggest that each
enetic form should be considered to represent a distinct
ntity (60).
Long QT syndrome (LQTS) is characterized by pro-
onged ventricular repolarization and a predisposition to
olymorphic ventricular tachycardia (torsades de pointes).
hree main subtypes exist: Romano-Ward syndrome,
hich is isolated LQTS inherited in an autosomal domi-
ant manner; Jervell and Lange-Nielsen syndrome (JLNS),
hich is associated with sensorineural hearing impairment
nd is inherited as an autosomal recessive trait; and
ndersen-Tawil syndrome, in which LQTS is one compo-
ent of a more complex phenotype (61,62).
Genetic studies have demonstrated at least 10 different
orms of LQTS, and several genes are involved in different
linical subtypes of LQTS, as well as other genetically
etermined arrhythmias (Table 2). KCNQ1 (LQT1) and
CNE1 (LQT5) encode for the alpha and beta subunits of
he catecholamine-sensitive components of the potassium
hannel of the cardiac delayed rectifier. Mutations in these
enes cause disease by a variety of mechanisms, including
aploinsufficiency and dominant negative effect (63). Mu-
ations in KCNQ1 are the most common in Romano-Ward
yndrome, found in about one-half of affected individuals.
omozygous mutations in either KCNQ1 or KCNE1 cause
he autosomal recessive JLNS.
KCNH2 (LQT2) and KCNE2 (LQT6) encode for the
lpha and beta subunits of the rapid component of the
otassium channel. Mutations in KCNH2 are the next most
ommon cause of LQTS, accounting for 35% to 40% of
c
m
s
1
g
g
s
W
m
m
m
u
i
t
i
d
t
c
e
3
p
l
(
f
c
m
(
i
w
R
m
i
m
C
a
o
d
c
f
p
d
a
a
a
g
r
R
1
2
3
O
p
t
a
(
a
e
i
i
a syndr
734 Robin et al. JACC Vol. 50, No. 8, 2007
Genetic Testing in CVD August 21, 2007:727–37ases. In contrast, KCNE2 is the least commonly identified
utation in LQTS. SCN5A (LQTS3) encodes the cardiac
odium channel. Mutations in this gene account for 10% to
5% of LQTS (63).
Until recently it was assumed that all LQTS-associated
enes involved ion channels. The discovery that ANK2, the
ene for the structural protein ankyrin B, LQTS4, demon-
trated that other types of genes can cause LQTS (64).
hile only found in a single family to date, the ANK2
utation seems to have a distinct clinical presentation, as
ost patients also manifest sinus bradycardia and paroxys-
al atrial fibrillation. Although the mechanism of disease is
ncertain, it may be that ankyrin B is involved in anchoring
ons channels in the cell membrane.
Recently, several genotype-phenotype studies have shown
hat each LTQS subtype has its own clinical characteristics,
ncluding subtle differences in the ST-T complex, and
ifferent triggers and risks for cardiac events. For example,
he risk for a cardiac event seems to be less for LQT1
ompared with both LQT2 and LQT3 (65). Furthermore,
ach subtype has a significant rate of nonpenetrance: LQT1
6%; LQT2 19%; and LQT3 10%. Lastly, mutations in the
ore region of the LQTS2 gene KCNE2 carry a greater
ikelihood of cardiac disease than even nonpore mutations
66).
Such studies are very valuable in differentiating the risks
or individual patients, and illustrate one manner in which
linical testing has an important role in the evaluation,
anagement, and prognostic counseling for these patients
67). For example, an implantable cardioverter defibrillator
s often used, but may be best for symptomatic individuals
ith the LQT3 phenotype (68) and one subtype of
omano-Ward syndrome, namely those patients who also
anifest syndactyly (69). Lastly, genetic testing is obviously
mportant in presymptomatic diagnosis of at-risk family
embers in order to prevent syncope and sudden death.
Clinical and Genetic Heterogeneity of Long QT S
Table 2 Clinical and Genetic Heterogeneity
Syndrome
Inheritance
Pattern Addition
Romano-Ward AD None
Jervell and Lange-Nielsen AR Sensorineur
Andersen-Tawil AD Physical dys
paralysis
*Clinical testing is available; †mutations in SCN5A also cause Brugad
Abbreviations as in Table 1.aution should be taken to ensure all first-degree relatives pre tested, as individuals may have a normal QTc duration
n ECG and yet be genotype positive with risk for sudden
eath (70).
Andersen-Tawil Syndrome is a rare autosomal dominant
ondition in which LQTS is associated with other mani-
estations, including a characteristic dysmorphic facial ap-
earance (low-set ears, wide set eyes, small mandible, fifth
igit clinodactyly, syndactyly, short stature, and scoliosis),
nd periodic muscle weakness (61,62). While the risk for
dverse cardiac events is present, the condition is most often
ssociated with a benign outcome (71). The responsible
enetic change is in KCNJ2, which encodes the inward
ectifier potassium channel 2.
ecommendations:
. Individuals with the clinical diagnosis of LQTS are rec-
ommended to consider genetic testing after counseling, as
there is evidence that genotype may help with direct optimal
treatment strategies. Testing is currently available commer-
cially. Not all insurance companies cover the costs of testing.
. Genetic testing should be offered to all first-degree relatives
regardless of QTc interval.
. If the patient is determined to be genotype positive, consid-
eration should be given to enrolling the patient in the
International Long QT Registry.
ther familial arrhythmias. Catecholaminergic polymor-
hic ventricular tachycardia is a poorly understood condi-
ion in which individuals manifest a variety of ventricular
nd supraventricular arrhythmias during exercise or stress
72). Unlike LQTS, these occur in a predictable manner. In
bout one-third of cases, a family history will reveal an
pisode of sudden death in an otherwise well person, often
n childhood.
Catecholaminergic polymorphic ventricular tachycardia is
nherited as an autosomal dominant trait, with about 50% of
ome
ng QT Syndrome
nifestations Genetic Loci/Genes % Patients
LQT1/KCNQ1* 50%
LQT2/LQT2* 35%–40%
LQT3/SCN5A*† 10%–15%
LQT4/ANK2 ?
LQT5/KCNE1* 2%–3%
LQT6/KCNE2* 1%
LQT8/CACNA1c 1%
LQT9/CAV3/SCN5A† 1%
LQT10/SCN4B 1%
ing impairment LQT1/KCNQ1*
LQT5/KCNE1*
ia; periodic LQT7/KCNJ2* 60%
ome and progressive cardiac conduction defects.yndr
of Lo
al Ma
al hear
morphatients having a mutation in RYR2, the gene for the
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August 21, 2007:727–37 Genetic Testing in CVDyanodine receptor (73). A second gene, CASQ2, causes an
utosomal recessive form of CPVT (74).
ecommendations:
. Genetic testing for mutations associated with CPVT is
commercially available and recommended based on the
treatment option for presymptomatic individuals.
Brugada syndrome is a rare autosomal dominant condi-
ion characterized by the following electrocardiographic
bnormalities in a structurally normal heart: elevated ST-
egment in leads V1 to V3, incomplete right bundle branch
lock, and susceptibility to ventricular arrhythmias, which
ccur most often in sleep or at rest (75,76). It is caused by
utations in SCN5A, which is also the gene for LTQ3.
nlike mutations in LQT3, which are gain of function, the
utations associated with Brugada syndrome are loss of
unction. SCN5A mutations also cause progressive cardiac
onduction defect (PCCD or Lenegre disease). Progressive
ardiac conduction defect is a common, but poorly defined,
utosomal dominant condition that can lead to complete
trioventricular block, syncope, and sudden death (77).
ther mutations in SCN5A have been reported in families
ith manifestations suggestive of PCCD, Brugada syn-
rome, and LQT3 (78–80). While there is limited corre-
ation of mutations in SCN5A or other genes with the
linical presentation, the genetic mutation is clearly not the
ole explanation for the observed phenotype (60). Under-
tanding the interactions between these and other proteins
s still incomplete, but will be needed if clinical testing is to
rovide the most useful information to patients, at-risk
amily members, and for population screening as well.
ecommendations:
. Commercial testing is available for patients with suspected
Brugada syndrome; however, the SCN5A gene accounts for
only 25% to 30% of clinically affected patients. Although the
yield is low, this testing may be helpful in borderline cases
and for presymptomatic screening in related family
members.
amilial PAH. Pulmonary arterial hypertension is an eti-
logically heterogeneous disease in which there is a progres-
ive increase in pulmonary artery pressure, eventually lead-
ng to heart failure and death (81). The 2 types of PAH, the
diopathic and the familial form, although rare, constitute a
ignificant portion of patients seen with this disease.
The genetic factors predisposing to primary pulmonary
ypertension (PPH) are slowly being unraveled. A known
amily history of PPH occurs in 6% to 12% of all reported
ases. This disease appears to be transmitted in an autoso-
al dominant pattern with incomplete penetrance and
vidence of genetic anticipation (decreasing age at death in
ubsequent generations). Vertical transmission is readily
pparent in most pedigrees, with many cases of father-to-
on transmission, thereby excluding X-linkage. Linkage
tudies have mapped the disease locus to a 3 cM interval on
hromosome 2q31-32 (locus PPH1) (82,83). Examinationf candidate genes within this interval led to the identifi-
ation of mutations in the BMPR2 gene, which predict a
isrupted protein and tracks with the disease. Inactivating
eterozygous mutations have been found throughout the
MPR2 gene in approximately 60% of patients with a
amily history and 26% of sporadic cases of PPH (84).
he 1038-amino-acid BMPR2 protein comprises ligand-
inding, kinase, and cytoplasmic domains. Mutations are
ow known to exist in each of the 13 exons that code for
hese specific regions. Interestingly, BMPR2 mutations
ave been identified in affected individuals with other risk
actors for PPH, including fenfluramine (“Fen-Fen”)
xposure (85).
ecommendations:
. Due to the heterogeneity of mutations in PAH, broad use of
testing for BMPR2 mutations is not recommended. How-
ever, testing among large families that may yield a signif-
icant number of asymptomatic carriers confers benefit and
allows for early detection of phenotypic expression using
screening mechanisms such as Doppler echocardiography or
right heart catheterization with exercise.
. In large affected families undergoing screening, the yield
in testing for the currently known BMPR2 mutations
remains less than 50%. Haplotype testing may be useful
in these large families if enough affected and unaffected
members exist (86).
onclusions
he era of genomic medicine is just beginning, and already
here are several new approaches to testing that enhance
iagnosis and management of cardiovascular disease. New
enetic tests for rare single gene disorders and more com-
on multifactorial disorders will appear gradually but
teadily over the coming years. This will change the ap-
roach to diagnosis, and will be a component of new
pproaches to preventative medicine. The physician will
ncreasingly be called upon to be a sophisticated consumer
f information that results from genetic testing. Ultimately,
he major gift of genetics to medicine will not be in the
dentification of genes responsible for disease, but in eluci-
ation of the molecular pathways that underlie health and
isease. Genomic medicine will have come of age at a point
hen diagnostic, predictive, and predispositional tests are
oupled to new approaches to prevention and management,
nformed by understanding of pathophysiology and armed
ith new targeted therapies.
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